These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14748200)

  • 21. The role of tazarotene in the treatment of psoriasis.
    Marks R
    Br J Dermatol; 1999 Apr; 140 Suppl 54():24-8. PubMed ID: 10731131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short contact therapy with tazarotene in psoriasis vulgaris.
    Veraldi S; Caputo R; Pacifico A; Peris K; Soda R; Chimenti S
    Dermatology; 2006; 212(3):235-7. PubMed ID: 16549919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic profile of tazarotene.
    Duvic M
    Cutis; 1998 Feb; 61(2 Suppl):22-6. PubMed ID: 9787988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
    Tanghetti EA;
    Cutis; 2000 Dec; 66(6 Suppl):12-8. PubMed ID: 11147086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis.
    Singh F; Weinberg JM
    J Drugs Dermatol; 2004; 3(2):141-3. PubMed ID: 15098968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tazarotene.
    Foster RH; Brogden RN; Benfield P
    Drugs; 1998 May; 55(5):705-11; discussion 712. PubMed ID: 9585866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
    Leyden JJ
    Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
    Coynik D
    Cutis; 2000 Dec; 66(6 Suppl):19-24. PubMed ID: 11147087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
    Poulin YP
    Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms of tazarotene action in psoriasis.
    Duvic M; Nagpal S; Asano AT; Chandraratna RA
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S18-24. PubMed ID: 9270552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
    Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
    Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tazarotene 0.1% cream for the treatment of photodamage.
    Phillips TJ
    Skin Therapy Lett; 2004 Apr; 9(4):1-2. PubMed ID: 15146262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
    Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS;
    J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-contact therapy with tazarotene in psoriasis vulgaris.
    Veraldi S; Schianchi R
    Dermatology; 2003; 206(4):347-8. PubMed ID: 12771482
    [No Abstract]   [Full Text] [Related]  

  • 36. Type I lamellar ichthyosis improved by tazarotene 0.1% gel.
    Marulli GC; Campione E; Chimenti MS; Terrinoni A; Melino G; Bianchi L
    Clin Exp Dermatol; 2003 Jul; 28(4):391-3. PubMed ID: 12823301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How and where tazarotene might fit into the current therapeutic armamentarium: an expert opinion.
    Koo JY
    Cutis; 1998 Feb; 61(2 Suppl):36-7. PubMed ID: 9787991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial.
    Shalita A
    Cutis; 2004 Oct; 74(4 Suppl):4-8. PubMed ID: 15543713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
    Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%.
    Diluvio L; Campione E; Paternò EJ; Mordenti C; El Hachem M; Chimenti S
    Pediatr Dermatol; 2007; 24(3):332-3. PubMed ID: 17542899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.